[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Morten Hostrup, PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":120},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,72,92,106],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100625314",false,"NCT07421024","Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle","Biased G Protein-Coupled Receptor Kinase Signaling Via β2-Adrenergic Receptors and Downstream Activation of Protein Synthesis-Regulating Kinases and Receptor Desensitization in Human Skeletal Muscle","ATR","Inclusion Criteria:\n\n* Healthy men\n* Age 21-45 years\n* BMI 25-35 kg\u002Fm\\^2\n* Body fat percentage 25-40%\n* Lean Mass Index 14-22\n\nExclusion Criteria:\n\n* Regular use of or allergy to β2-agonists\n* Serious adverse reactions to β2-agonists\n* Current smoker\n* Regular use of medication (except OTC allergy or analgesics)\n* Abnormal ECG before or after β2-AR stimulation\n* Hypertension\n* Reduced kidney function (eGFR \\\u003C 90 ml\u002Fmin\u002F1.73m\\^2)\n* Cardiovascular, metabolic, gastrointestinal, renal, or pulmonary disease\n* Psychiatric or neurological disorders affecting compliance\u002Fsafety reporting\n* Cancer history within the last 5 years\n* Substance abuse or alcohol intake \\>14 units\u002Fweek",true,"MALE","21 Years","45 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This longitudinal mechanistic physiological study examines biased β2-adrenergic receptor (β2-AR) signaling in human skeletal muscle, with emphasis on G protein-coupled receptor kinase (GRK)-mediated pathways. Participants will receive daily oral dosing of the GRK-selective long-acting β2-agonist ATR-258 for 8 weeks. Muscle biopsies and physiological measurements will quantify GRK-, cAMP\u002FPKA-, and β-arrestin-related signaling, fiber-type specificity, and potential receptor desensitization with repeated stimulation.",[28],"Overweight and Obesity",[30,31,32,33,34],"beta2","muscle","atr-258","adrenergic","biased signaling","NOT_YET_RECRUITING","2026-02-16",{"date":38,"type":39},"2026-02-19","ACTUAL",{"date":41,"type":22},"2026-02-20",{"date":43,"type":22},"2026-12-31",{"name":45,"class":46},"Morten Hostrup, PhD","OTHER",1,{"id":49,"slug":4,"hasResults":10,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100530591","NCT06188767","Testosterone-induced Muscle Memory and Underlying Mechanisms","Long-term Effects of Anabolic Androgenic Steroids on Muscle Growth Potential: Testosterone-induced Muscle Memory and Underlying Mechanisms","Inclusion Criteria:\n\n* Healthy men and women\n* BMI of \\\u003C26 and normal ECG and blood pressure\n\nExclusion Criteria:\n\n* Smoking\n* Chronic disease,\n* Use of prescription medication\n* Pain due to current or previous musculoskeletal injury\n* Resistance training more than once per week in the 12 months leading up to the intervention\n* Current or previous use of prohibited anabolic substances","18 Years","40 Years",{"count":57,"type":22},30,[59],"NA","The purpose of this project is to investigate underlying mechanisms of testosterone- and resistance training-induced muscle hypertrophy and muscle memory in humans.",[62],"Skeletal Muscle Physiology","RECRUITING","2025-04-07",{"date":66,"type":39},"2025-04-10",{"date":68,"type":39},"2025-04-01",{"date":70,"type":22},"2028-12-01",{"name":45,"class":46},{"id":73,"slug":4,"hasResults":10,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":78,"minAge":54,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":47},"100521246","NCT06067100","U-LABA\u002FICS Effects on Exercise Performance, Indacaterol","Physiological Response to U-LABA\u002FICS With Emphasis on Exercise Performance, Indacaterol","Inclusion Criteria:\n\n* Age 18-39\n* Physically active \\> 5 h weekly\n* Maximal oxygen consumption classified as high or very high\n\nExclusion Criteria:\n\n* Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist\u002Fcorticosteroid\n* ECG abnormality\n* ACQ score \\> 1.5\n* Severe bronchial hyperreactivity as determined by mannitol test\n* FEV1\u002FFVC ratio \\\u003C 0.7 determined with spirometry\n* Chronic illness determined to be a potential risk for participant during study\n* In chronic treatment with medication that may interfere with study results\n* Pregnancy\n* Smoker\n* Blood donation during the past 3 months","ALL","39 Years",{"count":57,"type":22},[59],"The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate",[84],"Exercise Performance",{"date":86,"type":39},"2025-04-09",{"date":88,"type":39},"2024-01-15",{"date":90,"type":22},"2026-12-01",{"name":45,"class":46},{"id":93,"slug":4,"hasResults":10,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":78,"minAge":54,"maxAge":79,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":105,"locationsCount":47},"100521208","NCT06066606","U-LABA\u002FICS Effects on Exercise Performance, Vilanterol","Physiological Response to U-LABA\u002FICS With Emphasis on Exercise Performance, Vilanterol",{"count":57,"type":22},[59],"The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate",[84],{"date":66,"type":39},{"date":103,"type":39},"2023-10-03",{"date":90,"type":22},{"name":45,"class":46},{"id":107,"slug":4,"hasResults":10,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":78,"minAge":54,"maxAge":79,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":118,"leadSponsor":119,"locationsCount":47},"100522009","NCT06077019","Role of Lung Function for Exercise Capacity in Well-trained Individuals","Role of Lung Function, Airway Inflammation and Bronchial Hyper Reactivity for Exercise Capacity in Well-trained Individuals",{"count":112,"type":22},60,[59],"The purpose of the project is to investigate exercise performance in humans following prolonged inhalation of beta2-agonists vilanterol + fluticasone furoate or indacaterol + mometasone furoate",[84],{"date":86,"type":39},{"date":103,"type":39},{"date":90,"type":22},{"name":45,"class":46},""]